Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{189827,
        author = {Shivam Mahendra Tiwari and Shraddha Khadse},
        title = {MEFANAMIC ACID IN THE TREATMENT OF OSTEOARTHRITIS},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {4647-4654},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=189827},
        abstract = {Mefenamic acid is a fenamate class non-steroidal anti-inflammatory drug widely employed in the management of pain and inflammation associated with musculoskeletal disorders, including osteoarthritis. Its therapeutic activity is primarily mediated through inhibition of cyclooxygenase enzymes, resulting in reduced synthesis of prostaglandins responsible for pain, inflammation, and fever. In addition to classical cyclooxygenase inhibition, mefenamic acid exhibits auxiliary pharmacological effects such as modulation of inflammatory cytokines, interference with ion channel activity, and suppression of nitric oxide–mediated inflammatory pathways, which collectively contribute to its analgesic efficacy. Despite its clinical usefulness, the long-term application of mefenamic acid in osteoarthritis is limited by gastrointestinal, renal, and hematological adverse effects, necessitating cautious dosing and patient selection.
Recent advances in pharmaceutical technology, including modified-release formulations, prodrug strategies, and nano-enabled drug delivery systems, have focused on improving the safety profile and therapeutic index of mefenamic acid. Parallel developments in computational drug design, such as molecular docking, quantitative structure–activity relationship analysis, and in silico ADMET prediction, have enhanced understanding of drug–target interactions and facilitated rational optimization of fenamate derivatives. This review summarizes the pharmacology, marketed formulations, mechanistic pathways, computational insights, formulation advances, safety considerations, and clinical evidence supporting the role of mefenamic acid in osteoarthritis management.},
        keywords = {Mefanamic acid, Osteoarthritis, COX inhibitors, Inflammation.},
        month = {January},
        }